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Abstract
Colorectal cancer is the second leading cause of cancer death in developed countries. Genome-
wide association studies (GWAS) have successfully identified novel susceptibility loci for
colorectal cancer. To follow-up on these findings, and try to identify novel colorectal cancer
susceptibility loci, we present results for genome-wide association studies (GWAS) of colorectal
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cancer (2,906 cases, 3,416 controls) that have not previously published main associations.
Specifically, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) using log-
additive models for each study. In order to improve our power to detect novel colorectal cancer
susceptibility loci, we performed a meta-analysis combining the results across studies. We selected
the most statistically significant single nucleotide polymorphisms (SNPs) for replication using 10
independent studies (8,161 cases and 9,101 controls). We again used a meta-analysis to summarize
results for the replication studies alone, and for a combined analysis of GWAS and replication
studies. We measured 10 SNPs previously identified in colorectal cancer susceptibility loci and
found eight to be associated with colorectal cancer (p-value range: 0.02 to 1.8 × 10−8). When we
excluded studies that have previously published on these SNPs, five SNPs remained significant at
p<0.05 in the combined analysis. No novel susceptibility loci were significant in the replication
study after adjustment for multiple testing, and none reached genome-wide significance from a
combined analysis of GWAS and replication. We observed marginally significant evidence for a
second independent SNP in the BMP2 region at chromosomal location 20p12 (rs4813802;
replication p-value 0.03; combined p-value 7.3 × 10−5). In a region on 5p33.15, which includes
the coding regions of the TERT-CLPTM1L genes and has been identified in GWAS to be
associated with susceptibility to at least seven other cancers, we observed a marginally significant
association with rs2853668 (replication p-value 0.03; combined p-value 1.9 × 10−4). Our study
suggests a complex nature of the contribution of common genetic variants to risk for colorectal
cancer.
Introduction
Colorectal cancer is the second leading cause of cancer death in developed countries, with
the lifetime risk estimated to be 5% to 6% (Ries et al., 2007). Linkage studies have
identified important rare germline mutations, such as those in the APC gene and DNA
mismatch repair genes, leading to severe syndromes, e.g. familial adenomatous polyposis
and Lynch syndrome (also called hereditary non-polyposis colorectal cancer) (de la
Chapelle, 2004). However, these high-penetrance mutations explain only a small fraction of
the genetic risk. To date, genome-wide association studies (GWAS) have identified fourteen
low-penetrance genetic variants that, together, explain approximately 8% of the familial
association of this disease (Broderick et al., 2007;Gruber et al., 2007;Houlston et al.,
2008;Houlston et al., 2010;Tenesa et al., 2008;Tomlinson et al., 2007;Tomlinson et al.,
2008;Zanke et al., 2007). Based on a recent method by Chatterjee and Park (Park et al.,
2010) that estimates the amount of familial association explained by common genetic
variants, we estimate that about 60 to 70 common variants (95% confidence interval: 31–
173) would explain approximately 17% (95% confidence interval: 11.6–35.8%) of the
familial association in colorectal cancer. Accordingly, we hypothesize that additional
common colorectal cancer susceptibility loci exist that yet have to be identified, and that
these loci can be identified through a genome-wide analysis of single nucleotide
polymorphism (SNP) data.
As has been demonstrated in studies of other common complex diseases, power to detect
novel loci is enhanced by performing meta-analysis that combine GWAS results (Zeggini
and Ioannidis, 2009). Therefore, we conducted a combined analysis of two recently
completed scans that have not previously published main associations, followed by a
replication study of the most significant findings using ten independent studies (Table 1;
Supplemental Note; Supplemental Table 1) to follow up on the currently established
colorectal cancer susceptibility loci and to try to identify additional susceptibility loci. The
GWAS meta-analysis included a total of 2,906 cases and 3,416 controls recruited as part of
the Colon Cancer Family Registry (CCFR), the Diet, Activity and Lifestyle Study (DALS),
the Prostate, Lung, Colorectal and Ovarian Screening Trial (PLCO), and the Women’s
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Health Initiative (WHI). The replication included a total of 8,161 cases and 9,101 controls
from the Nurses’ Health Study (NHS), the Health Professionals Follow-up Study (HPFS),
the Physicians’ Health Study (PHS), the Assessment of Risk in Colorectal Tumors In
Canada (ARCTIC), additional samples from DALS and CCFR, and case-control studies
from Germany, France, Israel, and Newfoundland. Most of these studies are part of the
Genetics and Epidemiology Colorectal Cancer Consortium (GECCO; details in
Supplemental Note).
Results
From the fixed-effects meta-analysis of GWAS scans, the inflation factor λ was 1.008,
indicating little evidence of residual population substructure, cryptic relatedness, or
differential genotyping between cases and controls (Supplemental Figure 1). When analyzed
separately, λ was similarly low for each scan (range: 1.005 to 1.01).
Initially, we attempted to validate the ten established susceptibility SNPs (p-value 5 × 10−8)
that had been published at the time we selected SNPs for replication (Broderick et al., 2007;
Gruber et al., 2007; Houlston et al., 2008; Tenesa et al., 2008; Tomlinson et al., 2007;
Tomlinson et al., 2008; Zanke et al., 2007). We found nominal evidence for association in
the same direction with p<0.05 from combined analyses of GWAS and replication for eight
of these ten loci (rs4939827/SMAD7, rs4779584/GREM1, rs16892766/EIF3H,
rs3802842/11q23, rs961253/BMP2, rs4444235/BMP4, rs9929218/CDH1, rs6983267/MYC;
Table 2). When we excluded results from studies that had been previously published
(Supplemental Table 2; Supplemental Figure 2), we found evidence for replication at p<0.05
for five out of nine SNPs. This latter analysis did not include rs6983267, since that SNP has
already been published on by a majority of the studies.
The most significant novel SNP in both the replication study, and in the combined analysis
of the GWAS and replication, was rs7315438 located on chromosome 12q24 near MED13L
(replication OR=0.92; replication p-value 1.0 × 10−3; combined OR=0.92; combined fixed-
effects p-value [pfixed] 5.6 × 10−6; combined random-effects p-value [prandom] 1.5 × 2=10−3;
Table 3; Supplemental Table 3). For two other SNPs, their association with colorectal cancer
was nominally significant within the replication study: rs4925386 located on chromosome
20q13 near LAMA5 (replication p-value 2.5 × 10−3; pfixed 2.1 × 10−4; prandom 0.015) and
rs16888522 located on 8q23.3 near EIF3H (replication p-value 4.1 × 10−3; pfixed 1.7 × 10−5;
prandom 4.5 × 10−4). We note that the rs4925386 SNP did not have strong evidence for
association in the random effects model. Since we selected rs4925386 for our replication
study, it has been identified as being associated with colorectal cancer by a published
GWAS (Houlston et al., 2010). The variant rs16888522 is in the region of rs16892766/
EIF3H, previously identified to be associated with colorectal cancer by a GWAS
(Tomlinson et al., 2008). The variant rs16888522/EIF3H was in weak linkage
disequilibrium (LD) with rs16892766/EIF3H (D′=0.255; r2=0.043; Supplemental Figure 4).
Conditional analysis, including both variants in the same model, resulted in less significant
results for both variants (Supplemental Table 4) and showed weak correlation between the
beta coefficients (r = −0.269), which suggests that these variants may not be independently
associated SNPs.
We identified five other loci with p<0.05 in our replication study and combined p-value
<10−4, (Table 3). The associated SNPs were located near BMP2, POLS, SLC8A1, TERT-
CLPTM1L and TPK1. One was in a region previously identified to be a colorectal cancer
susceptibility locus by a GWAS (rs4813802/BMP2): replication p-value 0.03; pfixed 7.3 ×
10−5; prandom 0.014; Table 3; Supplemental Figure 3; Supplemental Table 3). The higher p-
value for the random effects for this SNP reflects the fact that we observed evidence of
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heterogeneity among GWAS for rs4813802 (I2=76.1% and p = 0.06) (Ioannidis et al., 2007);
however, this was less pronounced among the replication studies (I2 =40.4% and p = 0.08)
suggesting that the result is consistent among studies after accounting for those that may be
subject to the “winner’s curse” (Garner, 2007). rs4813802/BMP2 was not in LD with the
known colorectal cancer susceptibility SNP in the region rs961253/BMP2 (D′=0.02, r2
<0.001) (Houlston et al., 2008), and the joint conditional analysis demonstrates the
independent association of both variants with colorectal cancer risk (correlation of beta
coefficients = 0.018; Supplemental Table 4; Figure 1).
For all SNPs in Table 3, we tested if the risk estimates of these variants may vary by mode
of inheritance or sex. While for some variants (rs4813802/BMP2, rs275454/POLS,
rs2373859/SLC8A1, and rs2853668/CLPTM1L), the recessive model tended to provide
stronger risk estimates and slightly lower p-values than the log-additive or dominant model,
the AIC value was >2 in all cases, indicating no statistical evidence for improvement over
the log-additive model (Supplemental Table 5). We also explored if results vary by sex and
found that for rs16888522/EIF3H the statistical evidence for association was stronger in
men (OR=1.25, p-value=0.002) than in women (OR=1.10; p-value=0.25), although the
effect estimates were in the same direction and similar in magnitude for both men and
women (Supplemental Table 6).
As a sensitivity analysis, we reran the combined fixed-effects meta-analysis leaving out one
study at a time for all SNPs in Table 2. In no case did the point estimate change >3%.
Further, all pfixed remained <5×10−3 except for when we removed the French study from the
analysis of rs4925386. In that case the OR remained similar (OR=0.94) but the p-value was
slightly attenuated pfixed=8.2×10−3.
Discussion
From the analysis of GWAS and replication, including a total of up to 11,067 cases and
12,517 controls, we found that SNPs in eight out of ten previously identified colorectal
cancer susceptibility loci were associated with the disease in our replication study at p<0.05.
We found evidence that a second SNP (rs4813802) near the BMP2 gene could be associated
with colorectal cancer, independently of the association with the previously identified
susceptibility SNP in that region (rs961253). Furthermore, our study reports for the first time
a potential new association of a variant in the TERT-CLPTM1L region with colorectal cancer
risk.
Our results provide further support for eight of ten previously identified GWAS hits. When
excluding studies that have previously published results on these known loci, five loci
showed evidence of replication in this independent subsample. The 8q24 SNP rs6983267
has already been heavily studied, including published reports for many of the studies
included in this paper (Figueiredo et al., 2011;Hutter et al., 2010), so we were not able to
examine independent replication of this SNP in this study. Among the remaining four loci
that did not show a significant association at p<0.05, three showed a trend towards
replication (with p<0.2 and an odds ratio in the same direction as the original GWAS
report). However, one SNP, rs10795668, did not show any evidence for association with
disease (OR=1.00; 95% CI: 0.93–1.08; p=0.96; Supplemental Figure 2). Several papers have
reviewed potential reasons for the lack of replication of GWAS findings (Chanock et al.,
2007;Kraft et al., 2009). As in any observational study, it is possible this represents either a
false positive in the initial report, or a false negative in this replication; although that seems
unlikely since both the discovery GWAS and this report are based on large, well-powered
studies. We used the same genetic model and similar trait definitions as the discovery
GWAS. Further, all studies were restricted to non-Hispanic Whites, limiting the possibility
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of differences in linkage disequilibrium patterns. It is possible that there may be differences
in the distribution of a key effect modifier between the studies used to identify rs10795668
and the studies presented in this paper. A full exploration of underlying gene-gene or gene-
environment interactions is beyond the scope of the current paper, but we did explore if the
effect of rs10795668 varied by sex. Although the results were not significant for either sex,
and the 95% CIs overlap, we do note an interesting pattern where the odds ratios are in
opposite directions for women and men, with men showing a trend in the direction of the
discovery GWAS. Specifically, we found ORwomen =1.07 (95% CI: 0.92–1.26; pfixed=0.38)
and ORmen =0.95 (95% CI: 0.84–1.07; pfixed=0.40).
The rs4925386/LAMA5 SNP was also recently identified in another GWAS meta-analysis
(Houlston et al., 2010). Although it was not a known colorectal cancer susceptibility loci at
the time that we selected SNPs for replication, this SNP met our criteria for selection, and
showed evidence for association in our replication sample. The rs4925386 variant lies in the
intron of the large laminin A5 protein encoding gene. As previously reported the variant is
in LD (r2>0.5) with four nonsynonymous SNPs in LAMA5 (Houlston et al., 2010). However,
the prediction of each of these amino acid changes is proposed to be benign. Overall, our
finding provides additional independent support that this variant is associated with
susceptibility to colorectal cancer.
None of the loci were significantly associated with colorectal cancer in our replication study
after adjusting for multiple testing (0.05/321=1.6 × 10−4), and none of the loci reached
“genome-wide significance” at the suggested p-values of 1.6 × 10−7 after accounting for the
two-stage design (details see method section) (Dudbridge and Gusnanto, 2008;Hoggart et
al., 2008;International HapMap Consortium, 2005;Pe’er et al., 2008;Risch and Merikangas,
1996;Wellcome Trust Case Control Consortium, 2007). However, for some of the variants
with p<0.05 in our replication and combined p-value <10−4, additional lines of evidence
provide support for the hypothesis that we may have identified genomic regions harboring
causal variants for colorectal cancer susceptibility. The variant rs4813802 is about 295.3kb
centromeric to the previously identified rs961253/BMP2 GWAS hit (Houlston et al., 2008);
both statistical models and LD data support the idea that these are independent signals. The
closest gene is bone morphogenetic protein 2 (BMP2). The new variant of interest,
rs4813802, is closer to BMP2 (49.2kb upstream) than the previously identified SNP
rs961253 (344.5kb upstream of BMP2). Interestingly, rs4813802 lies within an ENCODE
Digital DNAseI Hypersensitivity Cluster; it is also within an ENCODE region showing
H3K4Me1 enhancer associated histone marks (Rosenbloom et al., 2010), and the flanking
15 bp show strong placental mammal conservation by PhastCons (Siepel et al., 2005). While
not conclusive, all of these are consistent with the region flanking the SNP acting as a long-
range enhancer element, plausibly for BMP2. The BMP2 gene belongs to the transforming
growth factor-β (TGFβ) superfamily, which plays an important role in cell proliferation,
differentiation, and apoptosis (Massague, 2000). SNPs in five out of the 10 known colorectal
cancer SNPs have chromosomal locations in or near TGFβ superfamily genes (Tenesa and
Dunlop, 2009). Furthermore, loss in BMP signaling has been reported at the transition from
advanced adenoma to early cancer stage, compatible with a role in tumor progression
(Hardwick et al., 2008). Support for a role for BMP signaling in colorectal cancer comes
from the identification of mutations in the bone morphogenetic protein receptor, type IA
protein (BMPR1A) in juvenile polyposis (Howe et al., 2001). Individuals with familial
juvenile polyposis have a 20% risk of colon cancer by age 35 and 68% by age 60
(Schreibman et al., 2005). Our finding supports the possibility of allelic heterogeneity at the
BMP2 locus, which is consistent with findings for the 8q24 cancer locus (Al Olama et al.,
2009;Witte, 2007) and recent findings for height showing evidence for allelic heterogeneity
at as many as 19 loci (Lango et al., 2010). Similar to our finding, these 19 secondary signals
in height were rather distant (on average 177kb) from the initial index SNP that was found
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to be associated through GWAS (Lango et al., 2010). Accordingly, a comprehensive
exploration of already discovered colorectal cancer loci may uncover additional independent
variants. However, this example demonstrates that defining the boundaries of a
susceptibility locus may be challenging, because the SNP we identified (rs4813802) would
not have been included if we had defined the region around the initial index SNP (rs961253)
by LD.
The 8q24 region has been shown to have multiple independent variants that are associated
with cancers. Several of these variants are associated with more than one cancer, and some
cancers are associated with multiple variants in this region (Al Olama et al., 2009;Witte,
2007). Similarly, multiple variants associated with various cancer sites, including cancers of
lung, pancreas, testes, and bladder, as well as glioma, basal cell carcinoma, and melanoma
are found in the TERT-CLPTM1L region (Figure 2) (Hsiung et al., 2010;Landi et al.,
2009;McKay et al., 2008;Miki et al., 2010;Petersen et al., 2010;Rafnar et al., 2009;Shete et
al., 2009;Stacey et al., 2009;Turnbull et al., 2010;Wang et al., 2008). Ours is the first report
suggesting that a variant in the TERT-CLPTM1L region could be associated with colorectal
cancer. The variant rs2853668 is 4.9kb upstream of telomerase reverse transcriptase (TERT)
and 18.0kb downstream of cleft lip and palate transmembrane protein 1-like protein
(CLPTM1L). Both genes have been implicated in cancer: CLPTM1L has been shown to be
altered in cisplatin-resistant cell lines and potentially impacts apoptosis (Yamamoto et al.,
2001); TERT encodes for the telomerase catalytic subunit that is important for the replication
and stabilization of telomere ends, and subsequently impacts chromosome replication and
suppression of cell senescence. Malfunction of telomerase can result in chromosomal
abnormality and subsequent tumor formation (Rafnar et al., 2009). Our finding provides
further evidence that TERT-CLPTM1L is a general cancer susceptibility locus that impacts
critical function for cancer development, similar to the 8q24 region. The candidate gene in
the 8q24 loci is MYC, and, as noted by Johnatty and colleagues (Johnatty et al., 2010), these
two loci could act in concert. Specifically, the TERT promoter has several MYC (the nearest
gene to the 8q24 locus) binding sites (Wu et al., 1999); however, we did not observe a
statistically significant interaction between rs2853668/TERT-CLPTM1L and
rs6983267/8q24, MYC (p for interaction term=0.8).
The SNP rs7315438, which showed the most statistically significant association in both the
replication study alone, as well as in the combined meta-analysis of GWAS and replication
studies, is located on chromosome 12q24 about 76.9kb upstream of the T-box 3 protein
(TXB3). The SNP is also located 50.4kb downstream of MED13L, which encodes for a
subunit of the mediator complex, a large complex of proteins that functions as a
transcriptional coactivator for most RNA polymerase II-transcribed genes. Since it has been
implicated in transcription, this gene is a plausible candidate for further study. However, this
SNP is in a large LD region containing numerous other potential candidate genes, including
the kinase suppressor of RAS2 (KSR2).
Other SNPs identified as potentially associated with colorectal cancer in this study are
rs27545 (POLS), rs2373859 (SLC8A1) and rs1525461 (LOC643308/TPK1). The gene
closest to rs27545 is POLS (59 kb downstream) a DNA polymerase that is likely involved in
DNA repair and, hence, provides a potentially interesting candidate gene (Hubscher et al.,
2002). Other genes close to rs27545 are SRD5A1 (146 kb upstream), which converts
testosterone into the more potent dihydrotestosterone, and the methyltransferase NSUN2
(183 kb downstream), which methylates tRNA (Brzezicha et al., 2006). The SNP rs2373859
resides in the intronic region of SLC8A1 also known as NCX1, which is a cell membrane
protein that is involved in the rapid Ca(2+) transports (Annunziato et al., 2004). It is in a
gene rich region including other interesting candidates, such as MAP4K3 (954 kb upstream)
a member of the mitogen-activated protein kinases, which is involved in regulating both cell
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growth and death and has altered gene expression in many cancer types (Cuadrado and
Nebreda, 2010) and SOS1, which may act as a positive regulator of RAS (Freedman et al.,
2006). The closest gene to rs1525461 is TPK1 (195kb upstream). TPK1 is involved in the
regulation of thiamine metabolism (Timm et al., 2001). TPK1 flanks a gene rich region,
including several olfactory receptors but none of the genes has an obvious link to colorectal
cancer development. However, the assignment of SNPs to candidate genes should be done
with caution, as recently shown by additional fine mapping and in silico analysis of the
previously identified colorectal cancer loci 8q23.3 (EIF3H), 16q22.1 (CDH1/CDH3), which
suggested functional variation in unexpected candidate target genes (Carvajal-Carmona et
al., 2011).
Overall, our study suggests a complex nature of the contribution of common genetic variants
to risk for colorectal cancer, and suggests the need for additional studies to identify variants
with marginal effects, as well as studies to examine potential sources and role of
heterogeneity, including gene-gene and gene-environment interactions. We note that this
study focused on the log-additive model. Although we present results for other genetic
models for our top findings, our results may have been biased for SNPs that do not follow
this assumed log-additive model (Minelli et al., 2005). Further, this study was not set up to
investigate less frequent (allele frequency 1–5%) and rare variants (allele frequency <1%),
which have the potential to contribute substantially to the genetic susceptibility of colorectal
cancer (Bodmer and Bonilla, 2008;Cirulli and Goldstein, 2010;Manolio et al., 2009).
In summary, we replicated the majority of SNPs that have previously been found to be
associated with CRC in GWAS studies. We also report suggestive evidence for an additional
independent signal for colorectal cancer risk in the BMP2 locus and a possible new
association of colorectal cancer with a variant in the multi-cancer susceptibility locus around
TERT-CLPTM1L. Future studies are needed to try to replicate these findings, and if
successful, to identify the underlying variants directly responsible for the association, and to
study the underlying molecular mechanisms.
Materials and Methods
Study Participants
The studies and their abbreviations are listed in Table 1, and each study is described in detail
in the Supplemental Note. In brief, all cases were defined as colorectal adenocarcinoma
(International Classification of Disease Code 153–154) and confirmed by medical records,
pathologic reports, or death certificate. All cases and controls were self-reported as White,
which was confirmed in GWAS samples based on genotype data. All participants gave
written informed consent and studies were approved by the Institutional Review Board.
Study Design
The GWAS meta-analysis results are based on two scans. One GWAS was conducted within
the CCFR, including population-based cases and unrelated population-based controls from
three sites: USA, Canada, and Australia (Figueiredo et al., 2011). In total, 1,191 cases and
999 controls were successfully genotyped on the Illumina 1M/1M Duo platform and passed
all quality-control (QC) steps. The second scan was conducted across three US study
populations: the WHI and PLCO cohorts and the DALS population-based case-control
study. A total of 1,715 colon cancer cases and 2,417 controls were successfully genotyped
on the Illumina HumanHap 550K, 610K or combined Illumina 300K and 240K platforms
and passed all QC steps. After applying rigorous genotyping QC filters (see below), a total
of 378,739 directly genotyped single-nucleotide polymorphisms (SNPs) commonly shared
among the scans were included in the GWAS meta-analysis. To further boost the power and
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inform the ranking of SNPs we included summary statistics from a previously published
colorectal cancer GWAS (Colorectal Tumour Gene Identification Consortium, CORGI) in
the meta-analysis (The Institute of Cancer Research, 2008;Tomlinson et al., 2008).
However, to ensure independence of results from prior published scans we did not include
any CORGI results in any of the presented odds ratios or p-values.
Fixed effects p-values from the GWAS meta-analysis were used to select SNPs for
replication. We rank ordered the top SNPs. We used linkage disequilibrium (LD)
information in our controls to prune out “redundant” signals (defined as r2>0.5 for SNPs
≥100kb apart and r2>0.1 for SNPs <100kb apart). For the top five SNPs, with p<10−5, we
selected two other SNPs with r2>0.9 to ensure against potential genotyping failure. We then
went down the ranked list until we filled our SNP platform (total number of SNPs selected
for this project=343). SNPs were excluded based on p-value for heterogeneity <0.001 (n=1)
and poor clustering in visual inspection of cluster plots (n=3). If SNPs had a low design
score, we replaced them with an alternative SNP with r2>0.9. The lowest ranked SNP had p-
value 1.2 × 10−3. Our platform also included SNPs for the ten known colorectal cancer
susceptibility loci published in previous GWAS at the time we designed the platform. These
343 SNPs were genotyped in samples from DACHS, DALS, French, HPFS, NHS and PHS
studies (N=4,062 cases and 4,718 controls) (Table 1; Supplemental Note) and 306 SNPs
were successfully genotyped in all studies (see details below). After we selected SNPs for
replication, the ARCTIC genome-wide scan became available (769 cases and 665 controls),
and we used imputed data from that study for analysis of the 343 SNPs (12 SNPs were not
included due to low imputation quality or low HWE p-values).
As of April 2010, we had genotyped and analyzed the GWAS data and replication data from
ARCTIC, DACHS, DALS and the French case control study. We selected 32 SNPs with
p<0.1 in this replication set and/or a pfixed<10−4 in the combined replication and GWAS for
further genotyping in 2,550 cases and 3,539 controls, including additional samples from
NHS, PHS, and HPFS, and samples from MECC and NFCCR. The top SNPs were also
analyzed in a second set of data from the CCFR (780 cases and 780 controls). We present
results for the total replication sample of 8,161 cases and 9,101 controls.
Genotyping
Genomic DNA was extracted from blood samples or, in the case of a subset of PLCO
samples, from buccal cells using conventional methods.
GWAS for CCFR—Genotyping was completed on the Illumina Human1M and
Human1M-Duo Bead Array in accordance with the manufacturer’s protocol.
Sample exclusions: The following sample exclusion criteria were applied: call rate <95%
(n=75), any stripe (physical/analytical location on BeadChip) call rate <80% (n=9),
discordance with prior genotyping (n=3), non-White (n=29), samples that showed admixture
identified using the program STRUCTURE (n=33) (Falush et al., 2003; Pritchard et al.,
2000), high identity by descent using PLINK (n=2), and mismatch between called and
phenotypic sex (n=4). The final analysis was based on 1,191 cases and 999 controls.
SNP exclusions: SNPs were excluded if they did not overlap between the Illumina
Human1M and Human1M-Duo (n=190,301), were annotated as “Intensity Only” (n=8,263),
had call rates <90% on either the Illumina Human1M or Human1M-Duo (n=9,229), or by
study center or case-control status (n=12,695). When further restricting analysis to SNPs
with Hardy-Weinberg-Equilibrium (HWE) p>0.0001, MAF >0.05, and SNP call rate >0.98,
a total of 739,733 SNPs remained in the analysis.
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Average sample call rate was equal to 98.6% with >94% of samples having a call rate
>98%. Intra- and interplate replicate concordance rates were equal to 99.97% and 98.7%,
respectively.
GWAS for DALS, PLCO and WHI—Genotyping was completed using Illumina
HumanHap300 and HumanHap240S (PLCO), 550k (WHI, DALS) and 610k (DALS,
PLCO) BeadChip Array System on the Infinium platform in accordance with the
manufacturer’s protocol or as previously described for HumanHap300 and HumanHap240S
(Yeager et al., 2007).
Sample exclusions: Samples were excluded if the average call rate was <97% (DALS
n=110, PLCO n=63, WHI n=66) or there was a mismatch between called and phenotypic
sex (DALS n=6, PLCO n=1). To search for unexpected duplicates and closely related
individuals we calculated identity-by-state values. We excluded unexpected duplicates
(DALS n=2). Additionally, we excluded samples based on low concordance with prior
genotyping (DALS: n=10, WHI: n=1) as well as samples that did not cluster with the CEU
samples in principal component analysis including the three HapMap populations as a
reference (DALS n=20, PLCO n=2, WHI n=6). The final analysis was based on 698 cases
and 719 controls in DALS, 534 cases and 1,168 controls in PLCO, and 483 cases and 530
controls in WHI.
SNP exclusions: Because we combined data from different platforms, we took precautions
to exclude SNPs that do not perform consistently across platforms. This included SNPs
reported by Illumina as not performing consistently across platforms (n=78), SNPs found to
have more than one discordant call across the 550K and 610K platforms in HapMap Data or
our interplatform duplicates (n=185); and SNPs with different MAF calls on the two
platforms in our control populations (n=9). We further filtered SNPs within each study
(DALS, PLCO, WHI) based on MAF <0.05% or HWE in controls <0.0001. We applied a
call rate per chip type per study of >98%. A total of 392,361 SNPs passed all QC checks for
all three studies.
The average sample call rate was ≥98.8% in any of the three studies, and the concordance
rate of blinded duplicates (n=98 pairs) was >97%.
When we combined data across all scans a total of 378,739 autosomal SNPs were
successfully genotyped across all studies and used in our final GWAS meta-analysis of
2,906 cases and 3,416 controls.
Replication—Genotyping of 343 SNPs in DACHS, DALS, French, and the first sub-sets
of HPFS, NHS and PHS were carried out using BeadXpress technology according to the
manufacturer’s protocol. Problematic genotype clusters were visually inspected by lot
number and the calling algorithm was adjusted, if indicated. 35 SNPs were excluded from
the analysis due to poor cluster quality and 2 SNPs were excluded for being out of HWE
(p<0.0001) in controls of at least one study. The 306 SNPs in the replication had call rates
>92% across studies (average call rate per SNP per study 97.8%). MECC and NFCCR
samples were genotyped using Matrix-assisted Laser Desorption/Ionization Time-of-Flight
on the Sequenom® MassARRAY 7K platform (Sequenom, Inc., San Diego, CA). A total of
23 and 30 SNPs were successfully genotyped in MECC and NFCCR, respectively.
Additional samples from NHS, HPFS and PHS were genotyped on 29 SNPs using the
TaqMan® OpenArray® Genotyping Instrument Platform Assays (Applied Biosystems,
Carlsbad, CA). Overall, 32 SNPs had call rates >98% across studies (average call rate per
SNP per study 99.5%; Supplemental Table 7), indicating excellent quality.
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Two GWAS data sets (ARCTIC and CCFR II) became available after the GWAS meta-
analysis and were used only for replication as described above. ARCTIC has been
previously published (Zanke et al., 2007). Because ARCTIC was genotyped on the
Affymetrix platform with limited overlap of SNPs with the Illumina platforms, we made use
of imputed data for this study. Imputation was done with BEAGLE, using the phased
HapMap release 22 as the reference sample (http://ftp.hapmap.org/phasing/2007-08_rel22/)
(Browning and Browning, 2009). SNPs were removed if they were out of HWE (p<0.0001)
in the controls (n=1) or had an imputation r2<0.3 (n=11). For CCFR phase II, samples were
genotyped using the Illumina 1M Omni. Inclusion/exclusion criteria for cases in phase II
were consistent to those described for phase I.
Statistical Analysis
Study-specific analysis of GWAS data—To estimate the association between each
genetic marker and risk for colorectal cancer we calculated odds ratios (ORs) and 95%
confidence intervals (CIs) using log-additive genetic models relating the genotype dose (0, 1
or 2 copies of the minor allele) to risk of colorectal cancer. We adjusted for age, sex (when
appropriate), center and the first three principal components from EIGENSTRAT to account
for population substructure. The CCFR calculated these estimates with Cochran-Mantel-
Haenzsel analysis with strata defined by age, sex, and center.
Quantile-quantile (Q-Q) plots were assessed to determine whether the distribution of the p-
values in each study population was consistent with the null distribution (except for the
extreme tail; Supplemental Figure 1). To quantify the data in the QQ plots, we calculated the
inflation factor (λ) to measure the over-dispersion of the test-statistics from association tests
by dividing the mean of the test statistics by the mean of the expected values from a Chi-
Square distribution with 1 degree of freedom.
Combined analysis of GWAS—We conducted inverse-variance weighted fixed-effects
meta-analysis to combine odds ratio estimates from log-additive models or multiplicative
methods across individual study populations as described above. In this approach, we
weighted the beta estimates of each study by their inverse variance and calculated a
combined estimate by summing the weighted betas and dividing by the summed weights.
We chose to focus on fixed-effects because we only had a small number of studies. When
the number of studies is small, the between study variance may be poorly estimated,
resulting in deflated test statistics for association. As such, fixed-effects analysis is better
powered for discovery of novel variants (Kraft et al., 2009). We calculated I2, which is a
measure of the percentage of total variation across studies due to heterogeneity beyond
chance, and obtained the heterogeneity p-values based on Cochran’s Q statistic (Ioannidis et
al., 2007).
Study-specific analysis of replication data—To estimate the association between
each genetic marker and risk for colorectal cancer we calculated odds ratios (ORs) and 95%
confidence intervals using a log-additive genetic model relating the genotype dose (0, 1 or 2
copies of the minor allele) to risk of colorectal cancer and adjusting for age, sex, and study
center (as appropriate) in logistic regression analysis.
Combined analysis of replication data—We conducted inverse-variance weighted
fixed-effects meta-analysis to combine odds ratio estimates from log-additive models across
individual study populations and measured heterogeneity using I2 and Cochran’s Q statistic,
as discussed above.
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Analysis of combined GWAS and replication data—We again combined across
studies using inverse-variance weighted fixed effects meta-analysis. For novel SNPs with p
< 5 × 10−4 based on combined analysis of GWAS and replication, we also report random-
effects that incorporate potential heterogeneity into the effect estimate. For these SNPs we
also examined dominant, recessive and unrestricted genetic models and compared models by
calculating the Akaike information criterion (AIC). We performed stratified analyses and
evaluated whether the effects differed by sex. For novel SNPs in regions identified by
previous GWAS, we also performed a conditional analysis including both the newly and
previously identified SNPs in the region in one model to examine whether the effect of the
newly identified SNP can be explained by the existing one. To quantify the independence of
the novel SNPs from prior GWAS hits in the same region we calculated the variance-
covariance matrix and reported the correlation between the two betas. Finally, we performed
a sensitivity analysis where we removed the studies one at a time and examined the results
from the fixed-effect meta-analysis. We report any situations where removing one study
resulted in a >5% change in the OR point estimate and/or reduced the p-value of the
combined fixed-effects meta-analysis to be <5×10−3, since that would indicate the results
might be being driven by only one study.
Criterion for genome-wide significance—Based on an increasing number of papers
(Dudbridge and Gusnanto, 2008;Hoggart et al., 2008;International HapMap Consortium,
2005;Pe’er et al., 2008;Risch and Merikangas, 1996;Wellcome Trust Case Control
Consortium, 2007) providing a detailed discussion on the appropriate genome-wide
significance threshold, which all arrive at similar values in the range of 5 × 10−7 to 5 × 10−8
for White populations, we decided to use a p-value of 5 × 10−8 as genome-wide significance
threshold. To account for the two-stage approach (GWAS and replication) we calculated that
an overall p-value of 5 × 10−8 is equal to a combined two-stage p-value of 1.6 × 10−7 given
our sample sizes in the GWAS and replication and a threshold for selecting SNPs from the
GWAS of 1.2 × 10−3 as used here.
We used PLINK (Purcell et al., 2007; Purcell, 2011) and R (R Development Core Team,
2011) to conduct the statistical analysis and summarized results graphically using STATA
(StataCorp, 2009), snp.plotter (Luna and Nicodemus, 2007), and LocusZOOM (Pruim et al.,
2010).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Regional association results and LD structure for the associated region on chromosome
20p12.3/BMP2 locus
The top half of the figure has physical position along the x axis, and the −log10 of the meta-
analysis p-value on the y-axis. Each dot on the plot represents the result for one SNP. The
bottom half of the figure shows pairwise linkage disequilibrium (LD) for the genotyped
SNPs across the region. LD was measured as r2 and calculated using the control individuals
from the WHI, PLCO and DALS samples recruited from 53 centers across the USA. Darker
shading indicates higher levels of LD. The lines between the top and bottom half of the
figure connecting the same SNPs.
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Figure 2. Genetic variants associated with different cancer sites in the TERT-CLPTM1L region,
including the new finding for colorectal cancer for rs2853668
This figure shows the genomic region on chromosome 5.p.15.33 including the two genes
TERT and CLPTM1L. The top of the figure shows the genes with each exon represented by a
short vertical line. The line below the genes shows the location of the different SNPs that
have been associated with various cancer sites relative to the position of the genes (for
instance, the first two SNPs are located in the last intron of TERT). The triangle shows the
pairwise linkage disequilibrium (LD) of the SNPs. LD was measured as r2 and calculated
using the control individuals from the WHI, PLCO and DALS samples recruited from 53
centers across the USA. Darker shading indicates higher levels of LD.
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Table 1
Studies participating in the genome-wide association study (GWAS) and replication meta-analyses.
Study Name Abbreviation Cases Controls Total
GWAS
Colon Cancer Family Registry CCFR 1191 999 2208
Women’s Health Initiative WHI 483 530 1013
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial PLCO 534 1168 1702
Diet, Activity and Lifestyle Survey DALS 698 719 1417
Replication
Assessment of Risk in Colorectal Tumors In Canada ARCTIC 769 665 1434
Colon Cancer Family Registry Set II CCFR-II 780 780 1560
Darmkrebs: Chancen der Verhütung durch Screening DACHS 1731 1742 3473
Diet, Activity and Lifestyle Survey Set II DALS-II 691 720 1411
French Case-Control Study FRENCH 954 1060 2014
Health Professionals Follow-up Study HPFS 333 595 928
Molecular Epidemiology of Colorectal Cancer Study MECC 1686 1779 3465
Newfoundland Familial Colon Cancer Registry NFCCR 409 321 730
Nurses’ Health Study NHS 432 946 1378
Physician’s Health Study PHS 376 493 869
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